Investors

Investing in High Potential Markets with Significant Unmet Needs

Our vision is to become a leading biopharmaceutical company while addressing the significant unmet needs in Oncology and CNS

Scott Shively
President & CEO

Our Company Vision

Bexion Pharmaceuticals is commited to providing investors with the information needed to learn more about the strategic direction and progression of our organization.

Executive Summary
Presentations
Key Milestones
Investment History
Resources

Bexion Media

Press Release

Bexion Pharmaceuticals, Inc. Appoints Dr. Tariq Arshad as Chief Medical Officer

February 28, 2024|

COVINGTON, Ky., Feb. 28, 2024 /PRNewswire/ -- Bexion Pharmaceuticals, Inc., a clinical- stage biopharmaceutical company developing a new generation of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), today announced the appointment of Tariq Arshad, MD, MBA as Chief Medical Officer. Dr. Arshad is an oncologist with more than 25 years of experience and a successful track record of strategic planning, clinical development, and commercialization. "We are [...]

All press
  • Cincinnati Enquirer logo

Cincinnati Enquirer: 8 Cincinnati biotech companies with big steps to watch in 2020

January 1, 2020|

Excerpt: Cincinnati has become a nurturing place for bright ideas in biotechnology, and 2020 could bring big advancements. The Cincinnati USA Regional Chamber of Commerce estimates the industry contributes more than $3 billion to the area economy. Nearly 800 locations employ more than 13,000 workers who are making average salaries of about $100,000 a year. In alphabetical order, here are eight Cincinnati biotechs aiming for milestones in 2020. Bexion Pharmaceuticals [...]

Bexion in the news

Investment Pillars

Bexion is well positioned to achieve our ambitious targets and change the treatment landscape in Oncology and CIPN.

Highly Experienced Leadership Team

Learn more

BXQ-350 – Novel Mechanisms of Action

Learn more

Rapidly Advancing Clinical Development Plan

Learn more

High Potential Markets with Significant Unmet Need

Learn more

Advanced Manufacturing Process and Readiness

Learn more

Significant Capital Raised to Date

Learn more

Excellent IP position

Learn more

Highly experienced team of leaders and experts collectively are committed to advancing Bexion as a leader in the treatment of Oncology and CNS specific diseases.

Scott Shively
President & CEO

Meet our Team

BXQ-350’s novel mechanisms of action appears to decrease the bioactive molecule that tumor cells exploit to both provide chemotherapeutic resistance and fuel tumor proliferation.

Ray Takigiku
Founder and Chief Scientific Officer

Learn More About BXQ-350

The BXQ-350 clinical development plan is one that really excites me. The Bexion team has very intentionally chosen metastatic colorectal cancer and peripheral neuropathy based on the profile of it’s lead compound BXQ-350, and is rapidly progressing towards later stage clinical trials and commercialization.

Shabnam Kazmi, M.B.A.
Commercialization Advisor

Pipeline

Bexion is pursuing cancer and related treatments where there is a significant unmet need and high market potential.

Jim Beach
Operations

Metastatic ColorectalCancer (mCRC)
Chemotherapy InducedPeripheral Neuropathy(CIPN

Bexion has made significant advances in Manufacturing and has produced sufficient drug to support Phase two studies. This represents a real advantage to investors because we have derisked manufacturing and have set the hurdles higher for any competition.

Michael Gazda, Ph.D.
Chemistry, Manufacturing, and Controls

Learn more

Bexion Pharmaceuticals has secured a broad range of IP protective measures encompassing its clinical formulation, methods, and processes.

Christy Rothwell, Ph.D., J.D.
IP, Legal Counsel

Learn more

Investors have seen significant value and opportunity in Bexion and BXQ-350 supporting our ability to raise significant capital to fund operations and clinical development in key markets.

Joyce LaViscount
Chief Financial Officer

Learn more